Bill
Bill > A1136
NJ A1136
NJ A1136Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.
summary
Introduced
01/11/2022
01/11/2022
In Committee
01/11/2022
01/11/2022
Crossed Over
Passed
Dead
01/08/2024
01/08/2024
Introduced Session
2022-2023 Regular Session
Bill Summary
This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase deficiency prior to the patient undergoing chemotherapy. Dihydropyrimidine dehydrogenase deficiency is a disorder in which the human body experiences difficultly or is unable to breakdown chemotherapy drugs leading to a harmful reaction. Under the bill, health insurance plans in this State are to cover expenses incurred in conducting one test for dihydropyrimidine dehydrogenase deficiency every year.
AI Summary
This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase (DPD) deficiency, a disorder in which the body has difficulty breaking down certain chemotherapy drugs, before the patient undergoes chemotherapy. The bill also mandates that health insurance plans in New Jersey cover the cost of one DPD deficiency test per year, as well as any necessary prescription drug treatment for the condition, if the insurance policy provides prescription drug benefits.
Committee Categories
Health and Social Services
Sponsors (2)
Last Action
Introduced, Referred to Assembly Health Committee (on 01/11/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2022/A1136 |
| BillText | https://www.njleg.state.nj.us/Bills/2022/A1500/1136_I1.HTM |
| Bill | https://www.njleg.state.nj.us/Bills/2022/A1500/1136_I1.PDF |
Loading...